247 related articles for article (PubMed ID: 24603101)
21. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
22. Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome.
Schubert T; Danzig MR; Kotamarti S; Ghandour RA; Lascano D; Dubow BP; Decastro GJ; Benson MC; McKiernan JM
World J Urol; 2015 Jun; 33(6):847-52. PubMed ID: 25149472
[TBL] [Abstract][Full Text] [Related]
23. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors.
Alkhateeb SS; Van Rhijn BW; Finelli A; van der Kwast T; Evans A; Hanna S; Vajpeyi R; Fleshner NE; Jewett MA; Zlotta AR
J Urol; 2010 Jul; 184(1):81-6. PubMed ID: 20478593
[TBL] [Abstract][Full Text] [Related]
24. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
[TBL] [Abstract][Full Text] [Related]
25. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy.
Soria F; Pisano F; Gontero P; Palou J; Joniau S; Serretta V; Larré S; Di Stasi S; van Rhijn B; Witjes JA; Grotenhuis A; Colombo R; Briganti A; Babjuk M; Soukup V; Malmstrom PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha E; Ardelt P; Varkarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Sylvester R
World J Urol; 2018 Nov; 36(11):1775-1781. PubMed ID: 30171454
[TBL] [Abstract][Full Text] [Related]
26. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients.
Tilki D; Reich O; Svatek RS; Karakiewicz PI; Kassouf W; Novara G; Ficarra V; Chade DC; Fritsche HM; Gerwens N; Izawa JI; Lerner SP; Schoenberg M; Stief CG; Skinner E; Lotan Y; Sagalowsky AI; Shariat SF
J Urol; 2010 May; 183(5):1757-63. PubMed ID: 20299059
[TBL] [Abstract][Full Text] [Related]
27. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Lambert EH; Pierorazio PM; Olsson CA; Benson MC; McKiernan JM; Poon S
BJU Int; 2007 Jul; 100(1):33-6. PubMed ID: 17552951
[TBL] [Abstract][Full Text] [Related]
28. Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup.
Davis JW; Sheth SI; Doviak MJ; Schellhammer PF
J Urol; 2002 Feb; 167(2 Pt 1):494-500; discussion 501. PubMed ID: 11792905
[TBL] [Abstract][Full Text] [Related]
29. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
Kondylis FI; Demirci S; Ladaga L; Kolm P; Schellhammer PF
J Urol; 2000 Apr; 163(4):1120-3. PubMed ID: 10737479
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
[TBL] [Abstract][Full Text] [Related]
31. Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Matsumura Y; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
Int J Urol; 2022 Mar; 29(3):242-249. PubMed ID: 34902876
[TBL] [Abstract][Full Text] [Related]
32. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
[TBL] [Abstract][Full Text] [Related]
33. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
34. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy.
Contieri R; Tan WS; Grajales V; Hensley PJ; Martini A; Bree K; Myers A; Nogueras-Gonzalez G; Navai N; Dinney CP; Guo C; Kamat AM
BJU Int; 2024 Jun; 133(6):733-741. PubMed ID: 38374533
[TBL] [Abstract][Full Text] [Related]
35. The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: results from a single tertiary referral centre.
Naspro R; Finati M; Roscigno M; Pellucchi F; La Croce G; Sodano M; Manica M; Chinaglia D; Da Pozzo LF
World J Urol; 2021 Jun; 39(6):1917-1926. PubMed ID: 32696127
[TBL] [Abstract][Full Text] [Related]
36. Can Neutrophil-to-Lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?
Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi PF
Int Braz J Urol; 2019; 45(2):315-324. PubMed ID: 30785697
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series.
Chade DC; Shariat SF; Godoy G; Savage CJ; Cronin AM; Bochner BH; Donat SM; Herr HW; Dalbagni G
J Urol; 2010 Jul; 184(1):74-80. PubMed ID: 20546806
[TBL] [Abstract][Full Text] [Related]
38. T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy.
De Berardinis E; Busetto GM; Antonini G; Giovannone R; Gentile V
Int Urol Nephrol; 2011 Dec; 43(4):1047-57. PubMed ID: 21442469
[TBL] [Abstract][Full Text] [Related]
39. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design.
Mmeje CO; Guo CC; Shah JB; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol; 2016 Nov; 70(5):778-785. PubMed ID: 26922408
[TBL] [Abstract][Full Text] [Related]
40. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign.
Li R; Metcalfe MJ; Tabayoyong WB; Guo CC; Nogueras González GM; Navai N; Grossman HB; Dinney CP; Kamat AM
Eur Urol Oncol; 2019 May; 2(3):286-293. PubMed ID: 31200843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
